-
1
-
-
84954163383
-
Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer
-
Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Can Res 2015;21: 5469-79.
-
(2015)
Clin Can Res
, vol.21
, pp. 5469-5479
-
-
Peeters, M.1
Oliner, K.S.2
Price, T.J.3
Cervantes, A.4
Sobrero, A.F.5
Ducreux, M.6
-
2
-
-
84937143954
-
Metastatic colorectal cancer: Current state and future directions
-
Fakih MG. Metastatic colorectal cancer: Current state and future directions. J Clin Oncol 2015;33:1809-24.
-
(2015)
J Clin Oncol
, vol.33
, pp. 1809-1824
-
-
Fakih, M.G.1
-
3
-
-
70450195266
-
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
-
Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-27.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 519-527
-
-
Normanno, N.1
Tejpar, S.2
Morgillo, F.3
De Luca, A.4
Van Cutsem, E.5
Ciardiello, F.6
-
4
-
-
84883680951
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
-
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
-
(2013)
N Engl J Med
, vol.369
, pp. 1023-1034
-
-
Douillard, J.Y.1
Oliner, K.S.2
Siena, S.3
Tabernero, J.4
Burkes, R.5
Barugel, M.6
-
5
-
-
84906846009
-
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the CAPRI-GOIM trial
-
Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the CAPRI-GOIM trial. Ann Oncol 2014;25:1756-61.
-
(2014)
Ann Oncol
, vol.25
, pp. 1756-1761
-
-
Ciardiello, F.1
Normanno, N.2
Maiello, E.3
Martinelli, E.4
Troiani, T.5
Pisconti, S.6
-
6
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
De Schutter, J.4
Biesmans, B.5
Fountzilas, G.6
-
7
-
-
84925324704
-
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
-
Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33: 692-700.
-
(2015)
J Clin Oncol
, vol.33
, pp. 692-700
-
-
Van Cutsem, E.1
Lenz, H.J.2
Kohne, C.H.3
Heinemann, V.4
Tejpar, S.5
Melezinek, I.6
-
8
-
-
84929463919
-
Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy
-
Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 2015;21:1087-97.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1087-1097
-
-
Laurent-Puig, P.1
Pekin, D.2
Normand, C.3
Kotsopoulos, S.K.4
Nizard, P.5
Perez-Toralla, K.6
-
9
-
-
84878862323
-
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
-
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-73.
-
(2013)
Cancer Discov
, vol.3
, pp. 658-673
-
-
Bardelli, A.1
Corso, S.2
Bertotti, A.3
Hobor, S.4
Valtorta, E.5
Siravegna, G.6
-
10
-
-
84862999938
-
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
-
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
-
(2012)
Nature
, vol.486
, pp. 532-536
-
-
Misale, S.1
Yaeger, R.2
Hobor, S.3
Scala, E.4
Janakiraman, M.5
Liska, D.6
-
11
-
-
58749102224
-
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice
-
SantiniD, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, et al.High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. Oncologist 2008;13: 1270-5.
-
(2008)
Oncologist
, vol.13
, pp. 1270-1275
-
-
Santini, D.1
Loupakis, F.2
Vincenzi, B.3
Floriani, I.4
Stasi, I.5
Canestrari, E.6
-
12
-
-
79952698311
-
External quality assessment for KRAS testing is needed: Setup of a European program and report of the first joined regional quality assessment rounds
-
Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, et al. External quality assessment for KRAS testing is needed: Setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011;16:467-78.
-
(2011)
Oncologist
, vol.16
, pp. 467-478
-
-
Bellon, E.1
Ligtenberg, M.J.2
Tejpar, S.3
Cox, K.4
De Hertogh, G.5
De Stricker, K.6
|